Endocyte to Present at Upcoming Conferences

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

February 6, 2014 4:01 PM UTC

WEST LAFAYETTE, Ind., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following upcoming investment conferences in February:

Leerink Swann 2014 Global Healthcare Conference – Wednesday, Feb. 12, at 1:50 p.m. EST. The conference will be held at the Waldorf Astoria in New York City.
 
2014 RBC Capital Markets' Global Healthcare Conference – Wednesday, Feb. 26, at 8:30 a.m. EST. The conference will be held at the New York Palace in New York City. 

Webcast information can be accessed under "Events & Presentations" in the Investors & News section of Endocyte's website at www.endocyte.com.  All webcasts will be archived shortly after each live event and a replay will be available on the Company's website for 90 days following the conference.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.,
         (212) 362-1200, [email protected]
         Martina Schwarzkopf, Ph.D., Russo Partners,
         (212) 845-4292, [email protected]
         Tony Russo, Ph.D., Russo Partners,
         (212) 845-4251, [email protected]

Source: Endocyte, Inc.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Press Releases

Related Entities

RBC Capital